Status:

RECRUITING

A Study of Trastuzumab DeRuxtecan for Patients With Advanced HER2-pOsitive GaStric or GastroesoPhageal Junction AdEnocarcinoma Who Have Received a PrIor Trastuzumab-based Regimen Accompanied by a Disease RegistrY of Patients Treated With Conventional Therapies (PROSPERITY)

Lead Sponsor:

Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

Conditions:

HER2-positive Advanced Gastric Cancer

HER2-positive Gastroesophageal Junction Adenocarcinoma

Eligibility:

All Genders

18+ years

Brief Summary

Trastuzumab deruxtecan (T-DXD) as monotherapy is indicated for the treatment of adult patients with advanced HER2-positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma who have r...

Detailed Description

This non-interventional study will investigate the effectiveness of T-DXd, the patients demographic and clinical characteristics, treatment patterns including prophylactic medications and intervention...

Eligibility Criteria

Inclusion

  • Male or female adult patient (age ≥ 18 years) with HER2 + advanced gastric or GEJ adenocarcinoma who have received a prior trastuzumab based regimen
  • Histological or cytological confirmed diagnosis of advanced HER2 positive gastric cancer or GEJ
  • Documented HER2 + status (archival sample or recent sample prior 2L therapy)
  • Decision to newly initiate monotherapy T-DXd or conventional therapies per SMPC according to the physician's choice
  • Written dated and signed Informed Consent (ICF) to participate in the study

Exclusion

  • Patients who at time of data collection for this study are participating in or have participated in an interventional study that remains blinded
  • Pregnancy or breastfeeding
  • No specific exclusion criteria are defined, as patients will be treated according to the proposed indication statements in the SmPC.

Key Trial Info

Start Date :

December 5 2023

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

September 1 2027

Estimated Enrollment :

257 Patients enrolled

Trial Details

Trial ID

NCT05993234

Start Date

December 5 2023

End Date

September 1 2027

Last Update

December 11 2025

Active Locations (76)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 19 (76 locations)

1

KABEG Klinikum Klagenfurt am Wörthersee - Landeskrankenanstalten LKH

Klagenfurt, Austria, 9020

2

Ordensklinikum Linz GmbH Barmherzige Schwestern

Linz, Austria, 4010

3

Universitätsklinikum St. Pölten - Lilienfeld

Sankt Pölten, Austria, 3100

4

Medizinische Universität Wien

Vienna, Austria, 1090